Veppanu

(vepdegestrant)

Phase 2Small molecule

RRigel Pharmaceuticals

Veppanu is one of 69 small molecule programs targeting Function. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

FunctionNot yet recruiting

Breast CancerActive, not recruiting

FunctionPhase 1

Not yet recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Veppanu

RRigel Pharmaceuticals

Phase 2

4 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 5

Tianeptine

Pfizer

Preclinical

1 6

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 9

Bisphosphonate

Amgen

Preclinical

2 10

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Not yet recruiting

Function

NCT07231991

Phase 3Active, not recruiting

Breast Cancer

NCT05909397

Clinical

Trials by Indication[1]

Breast Cancer4 trials

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

Active, not recruiting· Pfizer logo

Pfizer·Phase 1/2·NCT06206837·71 enrolled

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Active, not recruiting· Pfizer logo

Pfizer·Phase 1/2·NCT06125522·11 enrolled

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)

Active, not recruiting· Pfizer logo

Pfizer·Phase 1·NCT05463952·6 enrolled

Show 1 more trial

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05909397·59 enrolled

ESS1 trial

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Completed· Pfizer logo

Pfizer·Phase 1·NCT06275841·12 enrolled

Infusion1 trial

A Study to Learn How a Tablet Compared With an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up Into the Blood in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT06911788·10 enrolled

CAR1 trial

A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants

Completed· Pfizer logo

Pfizer·Phase 1·NCT06005688·12 enrolled

Function1 trial

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

Not yet recruiting· Pfizer logo

Pfizer·Phase 1·NCT07231991·24 enrolled

2 more indications

Adult1 trial

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

Completed· Pfizer logo

Pfizer·Phase 1·NCT05538312·12 enrolled

Midazolam1 trial

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

Completed· Pfizer logo

Pfizer·Phase 1·NCT06256510·15 enrolled

Regulatory

FDA Approval Timeline[4]

May 1, 2026

VEPPANU

NDA NDA219835

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for vepdegestrant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — vepdegestrant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for vepdegestrant. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219835). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Veppanu. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Rigel Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRigel Pharmaceuticals

Patent Landscape[5]

Patent Cliff

Dec 1, 2037

Earliest patent expiration — generic entry possible after this date

Patent #Expires

11597720Dec 1, 2037

10899742Dec 1, 2037

10647698Jan 30, 2038

Veppanu

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Cancer4 trials

ESS1 trial

Infusion1 trial

CAR1 trial

Function1 trial

Adult1 trial

Midazolam1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News